{"id":"W4412522153","doi":"10.1016/s0140-6736(25)00684-1","title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Arena Pharmaceuticals","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Oncology; Cohort; Androgen deprivation therapy; Cancer; Clinical trial; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001250328,0.001446083,0.001940895,0.0002791135,0.0002336706,0.000930461,0.0006387052,0.0009873976,0.005252873],"category_scores_gemma":[0.001311679,0.0003834508,0.002402055,0.0003076231,0.000800349,0.0009643978,0.0003593981,0.002835978,0.0006851866],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008339663,"about_ca_system_score_gemma":0.00061236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001634602,"about_ca_topic_score_gemma":0.005076876,"domain_scores_codex":[0.9995649,0.0002430415,0.00001744743,0.00006619989,0.00003133773,0.00007708349],"domain_scores_gemma":[0.9995726,0.0001373585,0.0001072573,0.00003087142,0.00002551377,0.0001264586],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9588664,0.001270565,0.000724742,0.001395562,0.003213348,0.00005420173,0.0000605066,0.0009157775,0.002264975,0.0002542833,0.002742958,0.02823674],"study_design_scores_gemma":[0.9569886,0.03219364,0.005071962,0.0001227331,0.002239994,0.00008043992,0.00006703653,0.0005381715,0.0004050015,0.0005496106,0.001710446,0.0000322924],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9595309,0.02765769,0.0007206213,0.002536455,0.001220022,0.0006965968,0.001981525,0.0002326082,0.005423547],"genre_scores_gemma":[0.9836001,0.006747958,0.0006622728,0.00214843,0.0005539727,0.0004394271,0.001608366,0.0000390626,0.004200351],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005252873,"threshold_uncertainty_score":0.01757258,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05745369416498963,"score_gpt":0.3570725287255095,"score_spread":0.2996188345605199,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}